호흡기세포융합바이러스 진단 시장(2028년) - 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) : 제품별, 최종 용도별, 지역별, 경쟁

The Global Market for Respiratory Syncytial Virus (RSV) Diagnostics reached a valuation of USD 955.17 million in 2022 and is poised for substantial growth in the forecast period, boasting a projected Compound Annual Growth Rate (CAGR) of 8.01% through 2028. RSV, a highly contagious virus, is prevalent across all age groups, with a particular impact on infants and the elderly. While it may induce mild cold-like symptoms in healthy adults, it can lead to severe respiratory infections in vulnerable individuals. In the face of persistent respiratory health challenges worldwide, the significance of precise and timely RSV diagnostics cannot be overstated.

RSV stands as a formidable global health concern, resulting in millions of hospitalizations annually, with a pronounced effect on infants and young children. It is also a leading cause of lower respiratory tract infections in the elderly population. Swift diagnosis of RSV is imperative to initiate appropriate treatment and mitigate the virus's spread. The Global Respiratory Syncytial Virus Diagnostics Market assumes a pivotal role in addressing this critical requirement.

The global RSV diagnostics market is experiencing growth due to the escalating incidence of RSV infections worldwide. The virus maintains activity throughout the year, with peaks during the winter months in temperate regions. The market has capitalized on advancements in diagnostic technologies, such as Polymerase Chain Reaction (PCR) and immunofluorescence assays, facilitating rapid and precise RSV detection. Healthcare professionals and the general public are increasingly recognizing the significance of early RSV diagnosis, particularly in pediatric and geriatric populations, propelling the demand for diagnostic solutions. Point-of-care RSV testing has gained prominence, enabling healthcare providers to obtain expeditious results, thereby facilitating timely decision-making in patient care.

The outlook for the Global RSV Diagnostics Market appears highly promising, driven by continued technological advancements, heightened awareness, and the pressing need for swift and accurate diagnostics. As the healthcare sector continues to prioritize early detection and prevention, the market for RSV diagnostics is expected to undergo further expansion.

Key Market Drivers

Rising Respiratory Syncytial Virus incidence is Driving the Global Respiratory Syncytial Virus Diagnostics Market

Respiratory Syncytial Virus (RSV) is a common respiratory pathogen that affects people of all ages, but it is particularly dangerous for infants, the elderly, and individuals with weakened immune systems. In recent years, there has been a noticeable uptick in RSV cases worldwide, sparking concerns within the healthcare community. This surge in RSV incidence has had a significant impact on the global healthcare landscape, particularly on the Respiratory Syncytial Virus Diagnostics Market.

The COVID-19 pandemic led to widespread mask-wearing, social distancing, and remote learning, which effectively reduced the transmission of many respiratory viruses, including RSV. However, as these measures relaxed, people began to interact more, facilitating the spread of RSV. Babies born during the pandemic may have had reduced exposure to common viruses, leading to weaker immunity. This lack of exposure could make them more susceptible to RSV when they eventually encounter it. Although RSV vaccines are in development, none have been widely deployed. This absence of a vaccine contributes to the virus's continued circulation. RSV is known for its ability to mutate rapidly, leading to the emergence of new strains that can potentially cause more severe illness.

The rising incidence of RSV has driven the demand for more effective and accessible diagnostic tools. This surge in demand has led to significant developments in the Respiratory Syncytial Virus Diagnostics Market. Healthcare companies and researchers are investing more in RSV diagnostic solutions. This has led to the development of more accurate and rapid tests, such as PCR-based assays and point-of-care tests. Healthcare facilities, including clinics, hospitals, and laboratories, are expanding their diagnostic capabilities to accommodate the growing number of RSV cases. This includes the adoption of advanced diagnostic equipment and the training of medical staff to perform these tests effectively. Public health authorities are launching awareness campaigns to encourage people, especially parents and caregivers of young children, to seek testing for RSV at the first sign of symptoms. Timely diagnosis can help reduce the spread of the virus and improve patient outcomes. With the increasing preference for at-home healthcare solutions, there is a growing demand for RSV home testing kits. These kits provide convenience and can help individuals quickly determine if they have been infected.

Rising Pediatric Population Growth Fuels Growth in Global Respiratory Syncytial Virus Diagnostics

The global healthcare landscape is continuously evolving, and one of the significant factors influencing the healthcare market is the demographic changes across the world. A notable trend is the rising pediatric population, which is driving the demand for healthcare services and diagnostic tools. Among the many conditions affecting children, the Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants and young children. As the pediatric population grows, so does the need for efficient diagnostics and treatments for RSV. The world's pediatric population is on the rise, with many countries experiencing a baby boom or a sustained high birth rate. This demographic shift is a key driver behind the increased incidence of RSV infections. Young children, particularly those under the age of two, are more susceptible to RSV due to their developing immune systems. As more children are born, the pool of potential RSV cases expands, creating a greater need for diagnostic tests and treatments.

Early and accurate diagnosis of RSV is crucial for effective management and treatment. RSV shares symptoms with other respiratory infections, such as the common cold or influenza, making it challenging for healthcare professionals to diagnose without specialized tests. Diagnostic methods for RSV include molecular tests, rapid antigen tests, and viral culture. The rising pediatric population has led to increased demand for RSV diagnostic tests in healthcare facilities, including hospitals, clinics, and pediatricians' offices. Healthcare providers are recognizing the importance of timely diagnosis in preventing severe cases and complications, such as bronchiolitis and pneumonia, which can be life-threatening in infants and young children.

Major players in the global RSV diagnostics market are investing heavily in research and development to meet the growing demand for innovative diagnostic tools. Pharmaceutical companies are also developing antiviral drugs and vaccines to manage and prevent RSV infections. This influx of investments and research initiatives is shaping the RSV diagnostics market, making it more robust and responsive to the needs of the rising pediatric population.

Key Market Challenges

Limited Awareness and Education

One of the major challenges in the RSV diagnostics market is the limited awareness and education among healthcare professionals and the general public. Many individuals, including parents and caregivers, are unaware of the symptoms and risks associated with RSV. Consequently, there may be delays in seeking medical attention and getting the appropriate diagnostic tests done. Increasing awareness through healthcare campaigns and educational programs is crucial to combat this challenge.

High Cost of Diagnostic Tests

RSV diagnostic tests can be expensive, which poses a significant hurdle for patients, particularly in low- and middle-income countries. The high cost of tests, along with the associated medical expenses, can discourage individuals from seeking timely diagnosis and treatment. Reducing the cost of RSV diagnostics or developing more affordable testing options is essential to ensure widespread access to accurate detection.

Variability in Testing Methods

There is currently no single universally accepted diagnostic test for RSV. Multiple testing methods are available, including viral culture, polymerase chain reaction (PCR), and rapid antigen tests, each with its own advantages and limitations. This variability in testing methods can lead to inconsistencies in diagnoses and hinder the comparison of data across different regions. Standardizing RSV diagnostic protocols and promoting research for more accurate and accessible testing methods is crucial.

Seasonal Variability

RSV infections often exhibit a seasonal pattern, with peak cases occurring during the winter months in many regions. This seasonality can pose challenges for healthcare systems and diagnostic laboratories in terms of resource allocation and preparedness. During peak RSV seasons, healthcare facilities may become overwhelmed, leading to delays in testing and treatment. Developing strategies to cope with seasonal variability is essential to ensure timely diagnosis and patient care.

Limited Access to Healthcare Facilities

In some parts of the world, limited access to healthcare facilities can hinder RSV diagnosis. Rural and remote areas may lack the necessary infrastructure and trained healthcare professionals to perform diagnostic tests accurately. Telemedicine and point-of-care testing solutions can help bridge this gap and provide access to RSV diagnostics in underserved regions.

Emerging RSV Strains

RSV is known to mutate and evolve over time, leading to the emergence of new strains. These new strains can pose challenges for diagnostic tests designed to detect specific RSV variants. Continuous monitoring and research are essential to adapt diagnostic tools to account for emerging RSV strains and ensure their effectiveness.

Key Market Trends

Technological Advancements

The field of medical diagnostics has experienced a remarkable transformation in recent years, with technological advancements revolutionizing the way healthcare professionals detect and manage diseases. One such area of significant progress is the diagnosis of respiratory syncytial virus (RSV) infections. RSV is a common virus that can cause severe respiratory illness, particularly in infants and the elderly. As the world continues to grapple with the challenges posed by RSV, the global respiratory syncytial virus diagnostics market is being driven by a surge in technological innovations.

One of the most notable advancements in RSV diagnostics is the development of molecular diagnostic techniques. Polymerase Chain Reaction (PCR) and Reverse Transcription PCR (RT-PCR) have made it possible to detect RSV with exceptional sensitivity and specificity. These techniques can identify the virus's genetic material, allowing for early and precise diagnosis. Rapid diagnostic tests (RDTs) have gained popularity in recent years due to their ability to provide quick results at the point of care. Manufacturers have introduced RSV-specific RDTs that enable healthcare professionals to diagnose the virus within minutes, facilitating faster treatment decisions. NGS technologies have revolutionized the field of genomics and are now being applied to RSV diagnostics. NGS can provide comprehensive genomic information about the virus, helping researchers understand its evolution and potentially discover new therapeutic targets. Immunofluorescence assays (IFA) have been improved with the introduction of automated systems and more specific antibodies. This technology allows for the visualization of RSV antigens in patient samples, aiding in the rapid identification of the virus.

Advanced diagnostic technologies have significantly improved the accuracy of RSV diagnosis, reducing false negatives and positives. This has led to more effective patient management and better outcomes. Point-of-care testing and automated systems have shortened the time required to obtain test results. This is particularly critical for managing outbreaks and preventing the virus's spread in healthcare settings. The global RSV diagnostics market is experiencing robust growth as healthcare facilities and laboratories adopt these advanced technologies. Market players are investing in research and development to stay competitive, leading to a continuous cycle of innovation. The availability of rapid and accurate RSV diagnostics has made it easier for healthcare providers in remote or underserved areas to diagnose and manage RSV infections, improving healthcare equity.

Technological advancements are driving the global respiratory syncytial virus diagnostics market to new heights. The emergence of molecular diagnostics, point-of-care testing, NGS, and improved immunofluorescence assays has revolutionized the way healthcare professionals detect and manage RSV infections. These advancements not only enhance diagnostic accuracy and speed but also contribute to better patient outcomes and the overall control of RSV outbreaks. As technology continues to evolve, the outlook for the global RSV diagnostics market remains promising, with the potential to make significant strides in the prevention and management of this common respiratory virus.

Segmental Insights

Product Insights

Based on the product, the chromatographic immunoassay segment emerged as the dominant player in the global market for Respiratory Syncytial Virus Diagnostics in 2022. Chromatographic immunoassays are known for their rapid turnaround time. They provide quick results, often within minutes, making them valuable for immediate decision-making in clinical settings. These assays are typically easy to use and require minimal training. This simplicity is critical for healthcare professionals who need to conduct tests efficiently. Chromatographic immunoassays are well-suited for point-of-care testing. They can be used in various healthcare settings, including doctor's offices, clinics, and even at home, without the need for sophisticated equipment or a central laboratory. The manufacturing of chromatographic immunoassays is often cost-effective, leading to lower overall testing costs. This can be especially important for resource-limited settings. Advances in assay design have improved the sensitivity and specificity of chromatographic immunoassays, making them reliable tools for diagnosing RSV and other infectious diseases. Some chromatographic immunoassays can detect multiple pathogens simultaneously, providing a broader diagnostic picture. This is important for RSV diagnostics, as other respiratory viruses can cause similar symptoms. Over time, many chromatographic immunoassays have received regulatory approvals and gained acceptance in clinical practice, contributing to their dominance in the market.

End Use Insights

The hospital segment is projected to experience rapid growth during the forecast period. Hospitals are staffed with a range of healthcare professionals, including physicians, nurses, and laboratory technicians, who are trained to diagnose and manage RSV infections. This expertise ensures accurate diagnosis and appropriate patient care. Hospitals have infection control protocols in place to prevent the spread of RSV and other respiratory infections within healthcare facilities. Effective surveillance and diagnosis of RSV cases are critical components of these infection control measures. Hospitals often collaborate with research institutions and pharmaceutical companies in the development and evaluation of new RSV diagnostic technologies and treatment options. This close collaboration fosters advancements in RSV diagnostics within hospital settings. Hospitals provide both inpatient and outpatient care, allowing for comprehensive management of RSV cases. While severe cases may require hospitalization, mild cases can be diagnosed and treated in outpatient settings within hospitals. Hospitals typically have access to specialized laboratories and diagnostic equipment, such as molecular assays, immunoassays, and PCR (polymerase chain reaction) tests, which are used for accurate and sensitive RSV diagnosis. These facilities allow for precise and reliable detection of RSV in patient samples. Early diagnosis of RSV is essential for timely intervention and appropriate patient management. Hospitals are equipped with the necessary diagnostic tools and expertise to quickly diagnose RSV infections, enabling healthcare providers to initiate appropriate treatment and infection control measures promptly. RSV infections can range from mild cold-like symptoms to severe respiratory illnesses, including bronchiolitis and pneumonia, which may require hospitalization, especially in infants and young children. Due to the potential severity of RSV infections, hospitals play a crucial role in diagnosing and treating patients with RSV.

Regional Insights

North America emerged as the dominant player in the global Respiratory Syncytial Virus Diagnostics market in 2022, holding the largest market share in terms of value. North America, particularly the United States and Canada, experiences a relatively high prevalence of RSV infections, especially during the winter months. This higher incidence of RSV cases drives the demand for RSV diagnostic tests. North America boasts advanced healthcare infrastructure, including well-established clinical laboratories, research facilities, and healthcare institutions. This infrastructure supports the development, production, and distribution of RSV diagnostic tests, making it easier for healthcare providers to access and use these tests. The region is a hub for pharmaceutical and biotechnology companies specializing in infectious disease diagnostics and treatments. This fosters innovation and drives the development of cutting-edge RSV diagnostic technologies, contributing to market growth. North America has robust regulatory agencies like the U.S. Food and Drug Administration (FDA) and Health Canada that oversee the approval and clearance of diagnostic tests. Companies often prioritize obtaining regulatory approvals in these markets, which adds credibility to their products and facilitates market entry.

Key Market Players

• Becton, Dickinson, and Company

• Novartis AG

• Abbott Laboratories inc.

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• DiaSorin S.p.A.

• Merck KGaA

• Quidel Corporation

• Siemens Healthcare S.A.

• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Respiratory Syncytial Virus Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Syncytial Virus Diagnostics Market, By Product:

• Direct Fluorescent Antibody (DFA) Method
• Direct Fluorescent Antibody (DFA) Method
• Molecular Diagnostics
• Chromatographic Immunoassay
• Diagnostics Imaging
• Gel Microdroplets
• Flow Cytometry
• Others

Respiratory Syncytial Virus Diagnostics Market, By End Use:

• Hospitals
• Laboratory
• Clinics
• Homecare

Respiratory Syncytial Virus Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Syncytial Virus Diagnostics Market.

Available Customizations:

• Global Respiratory Syncytial Virus Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Respiratory Syncytial Virus Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Direct Fluorescent Antibody (DFA) Method, Direct Fluorescent Antibody (DFA) Method, Molecular Diagnostics, Chromatographic Immunoassay(Gravity Driven Test, Oligo chromatography (OC), Diagnostics Imaging, Gel Microdroplets, Flow Cytometry, Others)
  • 5.2.2. By End Use (Hospitals, Laboratory, Clinics, Homecare)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. North America Respiratory Syncytial Virus Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Area
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Syncytial Virus Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Area
      • 6.3.1.2.2. By Technology
  • 6.3.2. Canada Respiratory Syncytial Virus Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Area
      • 6.3.2.2.2. By Technology
  • 6.3.3. Mexico Respiratory Syncytial Virus Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Area
      • 6.3.3.2.2. By Technology

7. Europe Respiratory Syncytial Virus Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Area
  • 7.2.2. By Technology
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Syncytial Virus Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Area
      • 7.3.1.2.2. By Technology
  • 7.3.2. United Kingdom Respiratory Syncytial Virus Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Area
  • 7.3.3. Italy Respiratory Syncytial Virus Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Therapeutic Area
      • 7.3.3.2.2. By Technology
  • 7.3.4. France Respiratory Syncytial Virus Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Area
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Respiratory Syncytial Virus Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Area
      • 7.3.5.2.2. By Technology

8. Asia-Pacific Respiratory Syncytial Virus Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Area
  • 8.2.2. By Technology
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Respiratory Syncytial Virus Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Area
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Respiratory Syncytial Virus Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Area
      • 8.3.2.2.2. By Technology
  • 8.3.3. Japan Respiratory Syncytial Virus Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Area
      • 8.3.3.2.2. By Technology
  • 8.3.4. South Korea Respiratory Syncytial Virus Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Area
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Respiratory Syncytial Virus Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Area
      • 8.3.5.2.2. By Technology

9. South America Respiratory Syncytial Virus Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Area
  • 9.2.2. By Technology
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Respiratory Syncytial Virus Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Area
      • 9.3.1.2.2. By Technology
  • 9.3.2. Argentina Respiratory Syncytial Virus Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Area
      • 9.3.2.2.2. By Technology
  • 9.3.3. Colombia Respiratory Syncytial Virus Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Area
      • 9.3.3.2.2. By Technology

10. Middle East and Africa Respiratory Syncytial Virus Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Area
  • 10.2.2. By Technology
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Respiratory Syncytial Virus Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Area
      • 10.3.1.2.2. By Technology
  • 10.3.2. Saudi Arabia Respiratory Syncytial Virus Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Area
      • 10.3.2.2.2. By Technology
  • 10.3.3. UAE Respiratory Syncytial Virus Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Area
      • 10.3.3.2.2. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Respiratory Syncytial Virus Diagnostics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Application Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Becton, Dickinson, and Company
  • 14.5.2. Novartis AG
  • 14.5.3. Abbott Laboratories inc.
  • 14.5.4. Thermo Fisher Scientific Inc.
  • 14.5.5. Bio-Rad Laboratories, Inc.
  • 14.5.6. F. Hoffmann-La Roche Ltd.
  • 14.5.7. DiaSorin S.p.A.
  • 14.5.8. Merck KGaA
  • 14.5.9. Quidel Corporation
  • 14.5.10. Siemens Healthcare S.A.
  • 14.5.11. Quest Diagnostics Incorporated

15. Strategic Recommendations

16. About Us & Disclaimer